Candidate Gene in Predicting In Vivo Ovarian Cancer Response to Combination Therapy with Paraplatin and Paclitaxel

Candidate Gene in Predicting In Vivo Ovarian Cancer Response to Combination Therapy with Paraplatin and Paclitaxel

Saved in:

Bibliographic Details
Main Authors:	Ramin Mirhashemi, J. Fernando Arena, Tony Frudakis, Nicholas Lambrou, Jane Arboleda, Marsha Hunt, Maria Medranda, Hervy Averette, Manuel Penalver
Format:	Article
Language:	English
Published:	Wiley 2002-01-01
Series:	The Scientific World Journal
Online Access:	http://dx.doi.org/10.1100/tsw.2002.10
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Exploring the effects of paclitaxel-loaded zein nanoparticles on human ovarian carcinoma cells
by: Stefania Scicchitano, et al.
Published: (2025-03-01)

SELECTIVE INHIBITION OF KRAS SIGNALING BY COMBINATION OF LOW DOSE RAPAMYCIN AND PACLITAXEL IN VIVO
by: M. N. Yurova, et al.
Published: (2018-07-01)

Enhanced in vivo Stability and Antitumor Efficacy of PEGylated Liposomes of Paclitaxel Palmitate Prodrug
by: Wu X, et al.
Published: (2024-11-01)

Transgenic zebrafish embryos to evaluate the in vivo effects of different liposome-paclitaxel nanocarrier system
by: Andrea Persico, et al.
Published: (2025-05-01)

History of paclitaxel and oral paclitaxel – Clinical data and future
by: Ganesh Divekar, et al.
Published: (2020-01-01)

Unraveling the molecular mechanisms of paclitaxel in high-grade serous ovarian cancer through network pharmacology
by: Yihao Pei, et al.
Published: (2025-05-01)

A Novel HDAC6 Inhibitor Enhances the Efficacy of Paclitaxel Against Ovarian Cancer Cells
by: An-Jui Chi, et al.
Published: (2025-06-01)

Sulindac exhibits anti-proliferative and anti-invasive effects and enhances the sensitivity to paclitaxel in ovarian cancer
by: Shuning Chen, et al.
Published: (2025-04-01)

Effect of NIMA-related kinase 2B on the sensitivity of breast cancer to paclitaxel in vitro and vivo
by: Yahong Wang, et al.
Published: (2017-04-01)

Combination Therapy of Albumin-Bound Paclitaxel and Carboplatin as First Line Therapy in a Patient with Ovarian Cancer
by: K. N Srinivasan, et al.
Published: (2014-01-01)

Bavachin enhances paclitaxel sensitivity in ovarian cancer cells through modulation of mitochondrial function and ER stress
by: Sang-Jin Lee, et al.
Published: (2025-12-01)

The Impact of Carboplatin Dosing Design Using Adjusted Serum Creatinine on Carboplatin Plus Paclitaxel Therapy for Ovarian Cancer
by: Shu Kato, et al.
Published: (2025-04-01)

In Vitro and In Vivo Comparative Evaluation of a Shellac-Ammonium Paclitaxel-Coated Balloon versus a Benchmark Device
by: Congying Xia, et al.
Published: (2021-01-01)

Synthesis and Characterization of Poly(Lactic-Co-Glycolic Acid)–Paclitaxel (PLGA-PTX) Nanoparticles Evaluated in Ovarian Cancer Models
by: Sylwia A. Dragulska, et al.
Published: (2025-05-01)

The pharmacology of paclitaxel in cancer therapy
by: Jiang Xinmei
Published: (2025-01-01)

SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells.
by: David A Tumbarello, et al.
Published: (2016-01-01)

STUB1 suppresses paclitaxel resistance in ovarian cancer through mediating HOXB3 ubiquitination to inhibit PARK7 expression
by: Laigang Zhao, et al.
Published: (2024-11-01)

Efficacy of albumin-bound paclitaxel versus paclitaxel in esophageal cancer: a systematic review and meta-analysis
by: Jiayang Song, et al.
Published: (2025-08-01)

Combination of Cannabidiol with Cisplatin or Paclitaxel Analysis Using the Chou–Talalay Method and Chemo-Sensitization Evaluation in Platinum-Resistant Ovarian Cancer Cells
by: Jana Ismail, et al.
Published: (2025-02-01)

Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.
by: Fung Zhao, et al.
Published: (2014-01-01)

Phototriggerable 2',7-caged paclitaxel.
by: Radu A Gropeanu, et al.
Published: (2012-01-01)

Modern and minimally invasive formulations with paclitaxel
by: Andreea Crețeanu, et al.
Published: (2025-01-01)

Comparison of nab-paclitaxel, paclitaxel, and oxaliplatin-induced peripheral neuropathy: a cross-sectional cohort study
by: Terry Trinh, et al.
Published: (2025-04-01)

Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancer
by: Shao-Jing Wang, et al.
Published: (2025-03-01)

Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies
by: Anna Wawruszak, et al.
Published: (2025-12-01)

Author Correction: STUB1 suppresses paclitaxel resistance in ovarian cancer through mediating HOXB3 ubiquitination to inhibit PARK7 expression
by: Laigang Zhao, et al.
Published: (2024-12-01)

Proteogenomic approach to immunopeptidomics of ovarian tumors identifies shared peptide vaccine candidates
by: Jacopo Chiaro, et al.
Published: (2025-08-01)

Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer
by: Pierre-Luc Mercier, et al.
Published: (2011-10-01)

Curcumin increases the sensitivity of Paclitaxel-resistant NSCLC cells to Paclitaxel through microRNA-30c-mediated MTA1 reduction
by: Yimin Lu, et al.
Published: (2017-04-01)

Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.
by: Angela M Minassian, et al.
Published: (2011-01-01)

Comparative acute toxicity of intravenous paclitaxel and sirolimus in rats
by: Jing Xie, et al.
Published: (2025-01-01)

Severe skin toxicity due to weekly paclitaxel administration
by: Shruti Kate, et al.
Published: (2015-01-01)

“Nano-Paclitaxel” Unlocking Potential and Redefining Cancer Chemotherapy
by: Anuja Muley, et al.
Published: (2025-06-01)

Paclitaxel triggers molecular and cellular changes in the choroid plexus
by: Alemeh Zamani, et al.
Published: (2024-11-01)

The mechanism of paclitaxel induced damage on placental trophoblast cells
by: Yang Yu, et al.
Published: (2024-10-01)

Baseline differences in metabolic profiles of patients with lung squamous cell carcinoma responding or not responding to treatment with nanoparticle albumin-bound paclitaxel (nab-paclitaxel)
by: Peng Cao, et al.
Published: (2023-08-01)

Proteomic analysis reveals potential biomarker candidates in serous ovarian tumors – a preliminary study
by: Shona Pedersen, et al.
Published: (2025-04-01)

PENURUNAN NILAI HANTARAN TULANG PADA PENDERITA KARSINOMA NASOFARING DENGAN KEMOTERAPI BERBASIS PLATINUM: KOMBINASI NEOADJUVANT PACLITAXEL-CISPLATIN DAN PACLITAXEL-CARBOPLATIN
by: Cika Apriliana, et al.
Published: (2019-02-01)

Cell metabolomics analyses revealed a role of altered fatty acid oxidation in neurotoxicity pattern difference between nab-paclitaxel and solvent-based paclitaxel.
by: Jhih-Wei Huang, et al.
Published: (2021-01-01)

Whole genome analysis and in vivo safety assessment of probiotic candidate Lactobacillus acidophilus L177
by: Yunjiang Liu, et al.
Published: (2025-07-01)